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Alix and cellular paralogs HD-PTP and Brox contain
N-terminal Bro1 domains that bind ESCRT-III
CHMP4. In contrast to HD-PTP and Brox, expression
of the Bro1 domain of Alix alleviates HIV-1 release
defects that result from interrupted access to
ESCRT. In an attempt to elucidate this functional
discrepancy, we solved the crystal structures of the
Bro1 domains of HD-PTP and Brox. They revealed
typical ‘‘boomerang’’ folds they share with the Bro1
Alix domain. However, they each contain unique
structural features that may be relevant to their
specific function(s). In particular, phenylalanine
residue in position 105 (Phe105) of Alix belongs to
a long loop that is unique to its Bro1 domain. Concur-
rently, mutation of Phe105 and surrounding residues
at the tip of the loop compromise the function of Alix
in HIV-1 budding without affecting its interactions
with Gag or CHMP4. These studies identify a new
functional determinant in the Bro1 domain of Alix.INTRODUCTION
HIV-1 is an enveloped virus that requires the recruitment of
members of the host endosomal sorting complex required for
transport (ESCRT) machinery to sever budding viruses from
the cell (Bieniasz, 2009; Demirov and Freed, 2004; Morita and
Sundquist, 2004). These cellular factors are known to catalyze
membrane fission events necessary for the internalization and
membrane protein sorting into multivesicular bodies (MVB)
(Babst et al., 2002; Saksena et al., 2009; Wollert and Hurley,
2010;Wollert et al., 2009), and completion of cytokinesis (Carlton
and Martin-Serrano, 2007; Elia et al., 2011; Guizetti et al., 2011;
Morita et al., 2007). Recruitment of ESCRT members is essential
for these cellular processes and HIV-1 budding; they both
require the assembly of ESCRT-III factors or charged MVB
proteins (CHMPs) as well as VPS4, the AAA ATPase that cata-
lyzes ESCRT complex disassembly and release (Martin-Serrano
et al., 2003a; Morita et al., 2011; Stuchell-Brereton et al., 2007;
von Schwedler et al., 2003).Structure 19, 1485–1HIV-1 gains access to the ESCRT pathway by using short,
highly conserved sequences called Late (L) domains. Two L
domains with PT/SAP and LYPXnL sequences are found in the
p6 region of HIV-1 Gag. They bind Tsg101 and Alix, respectively
(Garrus et al., 2001; Martin-Serrano et al., 2001; Strack et al.,
2003; VerPlank et al., 2001), two cellular proteins that drive
independent HIV-1 budding pathways. Tsg101 functions in
HIV-1 release as a member of ESCRT-I (Martin-Serrano et al.,
2003b), an interaction that signals the recruitment of the down-
stream-acting ESCRT-III factors and VPS4. The Tsg101/PTAP
budding pathway is predominant in 293T cells and plays an
important role in HIV-1 release and infectivity from T cells (Dus-
supt et al., 2011; Fujii et al., 2009). Alix binds the LYPXnL motif
and drivesHIV-1 release from293T cells as a secondary pathway
(Fisher et al., 2007; Strack et al., 2003; Usami et al., 2007),
although it is sufficient for the release of Equine Infectious
Anemia Virus (EIAV), another lentivirus that contains only the
LYPXnL type L domain motif (Chen et al., 2005; Strack et al.,
2003). Importantly, Alix binding to the LYPXnL motif promotes
robust HIV-1 release from T cell lymphocytes and plays a role
in virus infectivity (Dussupt et al., 2011; Fujii et al., 2009). Alix
binds CHMP4 isoforms, linking Gag directly to the ESCRT
pathway (Fisher et al., 2007; Katoh et al., 2004; Martin-Serrano
et al., 2003a; Strack et al., 2003; Usami et al., 2007). It is therefore
clear that Alix serves as a crucial bridging factor between HIV-1
LYPXnL motif and host ESCRT pathway. Furthermore, Alix also
functions in the release of other viruses such as SIV (Zhai et al.,
2011), RSV (Dilley et al., 2010), HBV and HCV (Ariumi et al.,
2011; Watanabe et al., 2007), dengue fever (Pattanakitsakul
et al., 2010), and yellow fever (Carpp et al., 2011), which makes
it a broader target for therapeutic intervention of viral release.
Structural studies revealed that Alix comprises three distinct
domains: an N-terminal Bro1 domain, a LYPXnL binding
coiled-coil V domain, and a C-terminal Proline Rich Domain
(PRD) (Fisher et al., 2007; Kim et al., 2005; Lee et al., 2007).
The Bro1 domain binds CHMP4 isoforms, a key functional
interaction for the Bro1 domain required for membrane fission
(Carlton and Martin-Serrano, 2007; Doyotte et al., 2008;
Dussupt et al., 2009; Fisher et al., 2007; Kim et al., 2005; McCul-
lough et al., 2008; Morita et al., 2007; Odorizzi et al., 2003;
Usami et al., 2007). Interestingly, a CHMP4-independent Bro1
function in virus release was also reported (Bardens et al.,
2011; Popov et al., 2009) and a possible role inmembrane curva-
ture/modeling was attributed to the Bro1 domain on the basis495, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1485
Structure
A New Functional Determinant in Alix Bro1 Domainof its boomerang/banana-shaped structure (Fisher et al., 2007;
Kim et al., 2005; McMahon and Gallop, 2005; Odorizzi et al.,
2003). The central domain of Alix folds into a V-shaped structure
and is involved in interactions with retroviral Gag proteins (Fisher
et al., 2007; Lee et al., 2007) and Alix-Alix homodimerization,
a property believed to play a key role in Alix function (Pires
et al., 2009). The PRD interacts with several cellular factors
including Tsg101, CIN85, endophilin, ALG-2, andCep55 (Carlton
andMartin-Serrano, 2007; Chatellard-Causse et al., 2002; Fisher
et al., 2007; Lee et al., 2008; Martin-Serrano et al., 2003a, 2003b;
Missotten et al., 1999; Morita et al., 2007; Odorizzi, 2006;
Schmidt et al., 2003; Vito et al., 1999) and these interactions
link Alix to multiple cellular processes (Cabezas et al., 2005; Ma-
hul-Mellier et al., 2008; Pan et al., 2006, 2008; Tsuda et al., 2006;
Wu et al., 2002). Alix also interacts with Nedd4-1, an E3 ubiquitin
ligase that promotes HIV-1 release (Nikko and Andre´, 2007;
Sette et al., 2010). Similarly, functional interactions between
Alix yeast ortholog Bro1p and members of the ubiquitin
machinery occur (Luhtala and Odorizzi, 2004; Nikko and Andre´,
2007). Thus, Alix has numerous partners indicating that it serves
as a key scaffold protein in multiple cellular processes.
Alix binds two sites in HIV-1 Gag. The first site was identified
as the LYPXnL L domain motif in p6 that binds the second arm
of the Alix V domain (Fisher et al., 2007; Lee et al., 2007; Strack
et al., 2003). Mutations in either the LYPXnL motif or its binding
site in the V domain interfered with HIV-1 release (Dussupt
et al., 2009, 2011; Fisher et al., 2007; Fujii et al., 2009; Lee
et al., 2007; Popov et al., 2008; Strack et al., 2003). The second
site is carried within the first half of the Bro1 domain, which
engages the p6-adjacent Nucleocapsid (NC) domain of Gag
(Dussupt et al., 2009, 2011; Popov et al., 2008). Residue substi-
tutions in NC or within the first 200 residues of the Bro1 domain
compromised HIV-1 release (Dussupt et al., 2009, 2011; unpub-
lished data), emphasizing the critical role of NC-Bro1 domain
interactions in this process. Interestingly, the structure of the
Bro1-V fragment revealed that Bro1 is connected to the V
domain with a flexible linker that might allow relative re-orienta-
tion upon protein recruitment (i.e., NC domain and CHMP4, see
below) (Fisher et al., 2007). These observations suggest that
the Bro1 domain is a versatile scaffold that interacts with
numerous cellular partners(s).
CHMP4 isoforms bind a hydrophobic patch exposed on the
first half of the Bro1 domain (Fisher et al., 2007; Kim et al.,
2005; McCullough et al., 2008) and this interaction is key for
Alix facilitation of HIV-1 budding (Fisher et al., 2007; Usami
et al., 2007). CHMP4 isoforms multimerize as filaments believed
to coat the cytoplasmic side of cellular membranes as conical
structures, thus promoting fission (Fabrikant et al., 2009; Hanson
et al., 2008; Hurley andHanson, 2010; Lata et al., 2008;Weissen-
horn and Go¨ttlinger, 2011). Our recent studies demonstrated
that expression of the isolated Bro1 domain was sufficient
to stimulate HIV-1 release in the absence of L domains, thus
identifying Bro1 as the minimal functional unit of Alix (Dussupt
et al., 2009). Remarkably, Bro1-induced HIV-1 release requires
the NC domain in Gag and an intact CHMP4 binding site in
Bro1 (Dussupt et al., 2009), providing strong evidence that
Bro1-NC interactions are involved in CHMP4 recruitment.
Bro1 domains are found in other cell proteins including
HD-PTP, Brox, and Rhophilin, which have been associated1486 Structure 19, 1485–1495, October 12, 2011 ª2011 Elsevier Ltdwith signal transduction and endocytosis (Doyotte et al., 2008;
Ichioka et al., 2008; Peck et al., 2002; Toyooka et al., 2000).
We and others reported that HIV-1 Gag interacts with HD-
PTP, Brox, and Rhophilins (Dussupt et al., 2009; Popov et al.,
2009). Both HD-PTP and Brox Bro1 domains recruit CHMP4
isoforms, suggesting they might be able to promote HIV-1
release. However, in contrast to the Bro1 domain of Alix, the
Bro1 domains of HD-PTP and Brox (and their respective full-
length proteins) failed to function in HIV-1 release, indicating
that the Bro1 domain of Alix contains unique functional determi-
nant(s). To define such region(s), we determined the crystal
structures of the Bro1 domains of HD-PTP and Brox and
compared them with that of Alix. As expected, the Bro1
domains of HD-PTP and Brox folded into the typical boomerang
shape. Comparison of these Bro1 domains revealed structural
differences at the loops that connect the secondary structures,
the most striking of which is a distinctive loop in the Bro1
domain of Alix that centers at residue phenylalanine 105
(Phe105). Importantly, disruption of residues at the tip of
Phe105 loop severely inhibited Alix and Bro1-induced HIV-1
release, without affecting their ability to interact with Gag or
CHMP4. These studies identify a new functional determinant
in the Bro1 domain of Alix.
RESULTS
Unlike HD-PTP and Brox, the Bro1 Domain of Alix
Triggers HIV-1 Release
HD-PTP and Brox are two Alix cellular paralogs that were linked
to the endosomal sorting pathway as well as to other cellular
processes (Doyotte et al., 2008; Ichioka et al., 2008; Toyooka
et al., 2000). Both HD-PTP and Brox are predicted to contain
Bro1 domains based on their sequences and abilities to interact
with the ESCRT-III component CHMP4 and association with
endosomal compartments (Doyotte et al., 2008; Ichioka et al.,
2008; Ichioka et al., 2007). We previously found that overexpres-
sion of the isolated Bro1 domain of Alix was sufficient to rescue
virus release defects of the HIV-1 PTAP-/YP mutant lacking all
known L domains PTAP and LYPXnL, and this rescue required
the NC-domain (Dussupt et al., 2009). Moreover, Bro1-mediated
virus release rescue required an intact CHMP4 binding site,
suggesting that Bro1-NC interactions play a key role in linking
Gag to members of the host ESCRT pathway (Dussupt et al.,
2009). Here we confirm that the Bro1 domains of Alix, HD-PTP,
and Brox interact with the NC-p6 domains of HIV-1 Gag in
pull-down assays and that NC is sufficient to capture the
three Bro1 domains (Figure 1A) (Dussupt et al., 2009). Because
of these interactions and the ability of HD-PTP Bro1 and Brox
to bind CHMP4 isoforms, we tested whether the Bro1 domains
or the full-length proteins of HD-PTP and Brox can also stimulate
HIV-1 release. Overexpression of either the full length proteins
(Figure 1B, lanes 5–8) or the isolated Bro1 domains failed to
rescue the release-defective HIV-1 mutant viruses (Figure 1B,
lanes 1–4), indicating that only the Bro1 domain of Alix functions
in the HIV-1 virus rescue assay. These results also indicated that
binding Gag and CHMP4 are required but not sufficient for Bro1
function in HIV-1 release, suggesting that the Alix Bro1 domain
contains additional key and unique functional determinants
necessary for virus separation from the cell.All rights reserved
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Figure 1. Role of the Bro1 Domains in HIV-1 Release
(A) The Bro1 domains of Alix, HD-PTP and Brox bind HIV-1 NC domain. GST,
GST-NCp6, or GST-NC proteins were expressed in E. coli, captured on
Glutathione conjugated beads and subsequently incubated with lysates from
293T cells expressing either the HA-tagged version of the Bro1 domain of Alix
(HA-Bro1, left panel), HD-PTP (HD-Bro1, central panel) or Brox (Brox, right
panel). Captured proteins and cell lysates were analyzed by SDS-PAGE and
western blotting using anti-HA antibody and the expression of GST fusion
proteins was visualized by Coomassie blue staining.
(B) The Bro1 domains of HD-PTP and Brox do not promote HIV-1 release.
Overexpression of both full length Alix and its isolated Bro1 domain rescue
budding defects of HIV-1 PTAP- (lane 6) and PTAP-/YP- (lane 2) mutant
viruses, respectively. 293T cells were transfected with pNL4-3 PTAP-/YP-
proviral DNA alone (lane 1), with HA-Alix Bro1 (lane 2), HA-HD-Bro1 (lane 3), or
HA-Brox, or with pNL4-3 PTAP- proviral DNA alone (lane 5), with HA-Alix (lane
6), HA-HD-PTP (lane7) or HA-Brox (lane 8). Cells and viruses were collected
24 hr post-transfection and their protein content was analyzed by SDS-PAGE
and western blot using the indicated antibodies.
Table 1. Crystallographic Data collection and Refinement
Statistics
Space group
Brox HD-PTP
P63 P1
Unit cell (a, b, c) (A˚) 189.2, 189.2, 49.5 37.5, 61.3, 80.6
(a, b, g) () 90, 90, 120 85.9, 81.3, 88.0
Wavelength (A˚) 1.075 1.033
Resolution (A˚) 50-1.95 50-1.95
Last resolution shell (A˚) 1.99-1.95 1.99-1.95
Number of reflections
(total/unique)
439778/74479 174637/49890
Completeness (%) 99.8 / 100.0a 97.2 / 89.5a
I/s(I) 12.8 / 2.7a 25.2 / 3.3a
Rmerge (%)
b 11.0 / 54.7a 8.8 / 35.7a
Number of protein/
hetero-atoms
3041 / 65 5764 / 45
Rmsd bond lengths 0.012 A˚ 0.007 A˚
Rmsd bond angles 1.452 0.94
Rwork
c 14.89% 17.22%
Rfree
d 16.71% 21.53%
Ramachandran plote 97.3%/2.7%/0%/0% 94.0%/ 6%/ 0%/0%
PDB code 3R9M 3RAU
aNumbers correspond to the last resolution shell.
b Rmerge = Sh Si jIi(h) - < I(h) > j / ShSi Ii(h), where Ii(h) and < I(h) > are the ith
and mean measurement of the intensity of reflection h.
c Rwork = ShkFobs (h)j-jFcalc (h)k / ShjFobs (h)j, where Fobs (h) and F calc (h)
are the observed and calculated structure factors, respectively. No I/s
cutoff was applied.
dRfree is the R value obtained for a test set of reflections consisting of
a randomly selected 5% subset of the data set excluded from refinement.
e Residues in core (most favorable), allowed, additional allowed, and dis-
allowed regions of the Ramachandran plot as reported by Procheck.
Structure
A New Functional Determinant in Alix Bro1 DomainThe Bro1 Domains of HD-PTP and Brox Adopt a Similar
Boomerang Shape as the Bro1 Domain of Alix
HD-PTP and Brox were predicted to contain Bro1 domains
similar to that found in Alix based on their sequences and ability
to bind CHMP4 and associate with endosomal compartments
(Ichioka et al., 2007; Katoh et al., 2004). Despite these simi-
larities, the three Bro1 domain–containing proteins differ func-
tionally (Figure 1) (Doyotte et al., 2008; Dussupt et al., 2009),Structure 19, 1485–1suggesting potential structural differences that may be relevant
for HIV-1 release. To assess this hypothesis, we carried out
structural studies of the Bro1 domains of HD-PTP and Brox.
The Bro1 domains of HD-PTP (residues 2-361) and the Brox
(residues 2-374) were expressed in Escherichia coli, purified,
and crystallized. The structures were determined at 1.95 A˚ for
both HD-PTP and Brox Bro1 domains (Table 1 and Figures
2A–2C). The Bro1 domain of HD-PTP contains ten a helices
and three short b strands, similar to that of Alix. In contrast, the
Bro1 domain of Brox contains an additional a helix near its C
terminus that packs against its hydrophobic core with its shorter
a1 helix, and a prominent long loop between a9 and a10 helices,
as discussed in the next section (Figure 2C). Superposition of the
three Bro1 domains indicated that the Brox Bro1 domain devi-
ates most compared with Alix (Fisher et al., 2007) (20EW) and
HD-PTP, with a root mean square deviation (rmsd) of 2.35 A˚
between Brox and Alix, and 1.65 A˚ between HD-PTP and Alix.
This is perhaps not surprising because the sequence identity
between Brox and Alix is only 22%, whereas that between
HD-PTP and Alix is 29%. In comparison, the two Bro1 domain
structures of HD-PTP in the crystallographic asymmetric unit
has a rmsd of 0.68 A˚ compared with each other, and the yeast
Bro1 domain structure (Kim et al., 2005) (1ZB1) has a rmsd of
1.89 A˚ and a sequence identity of 26% compared with Alix.495, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1487
AC
B
D
Figure 2. Structural Superposition of the Three
Bro1 Domains
The Bro1 domains of Alix, HD-PTP and Brox are shown as
wheat, cyan and green ribbons, respectively in (A–C), and
superimposed as Ca traces in (D). Residue Phe105 of Alix
is shown as red spheres in (A) and (D), and reidue Pro299
of Brox is shown as magenta spheres in (C) and (D). The
secondary structures as well as the N- andC-termini of the
three Bro1 domains are marked in (A–C). See also Fig-
ure S1.
Structure
A New Functional Determinant in Alix Bro1 DomainAlix has been shown to bind the C-terminal tail of CHMP4 iso-
forms near a concave surface of the Bro1 domain (McCullough
et al., 2008). The binding pocket is composed of residues from
a5-7, and the C-terminal loop (McCullough et al., 2008). These
CHMP4 binding residues are largely conserved among Alix,
HD-PTP, and Brox, and they form similar concave binding
pockets. Upon superimposition of the Bro1 domains from HD-
PTP and Brox onto the Alix Bro1:CHMP4B peptide complex
structure (3C3Q) (McCullough et al., 2008), it is apparent that
the CHMP4B peptide can be readily accommodated by Bro1
domains from both HD-PTP and Brox (Figure 3). In addition
to several hydrogen bonds involving acidic residues at the
N-terminus of CHMP4B, the main binding interface is composed
of the same set of hydrophobic residues from CHMP4B M214,
L217, W220, and M224 located at hydrophobic pockets formed
by the HD-PTP or Brox a5-7 helices and the C-terminal loop
(Figures 3; see Figure S1 available online). For example, K147
and K202 in Alix are involved in packing against the CHMP4B
W220 sidechain, and the equivalent residues K141 and K192 inA B
Figure 3. Models of HD-PTP and Brox in Complex with a CHMP4B peptide
The Alix Bro1 domain in complex with a CHMP4B peptide (McCullough et al., 2008) is shown in
Brox:CHMP4 complex structures are shown in (B) and (C), respectively. The CHMP4Bpeptides are col
with critical binding residues show as sticks and labeled. The Bro1 domain residues in contact with t
and labeled in black, and residues hydrogen-bonded to CHMP4B shown as sticks. Hydrogen bonds
1488 Structure 19, 1485–1495, October 12, 2011 ª2011 Elsevier Ltd All rights reserveHD-PTP and K141 and R198 in Brox also form
similar W220 binding pockets in the modeled
complex structures. Notably, the key hydro-
phobic CHMP4B residues are conserved in
CHMP4A and CHMP4C and bind Alix Bro1 in
a similar mode (McCullough et al., 2008). It istherefore likely that both HD-PTP and Brox are capable of
binding different CHMP4 isoforms, similar to the Alix Bro1
domain.
In contrast to the clear CHMP4 binding pockets for HD-PTP
and Brox, the location of the NC binding site(s) at the Bro1
domains is not clear, largely because of the lack of structural
information on NC-Bro1 interaction. Mapping the Bro1 domain
sequence conservation onto the surface of the structures shows
that conserved residues are adjacent to each other to form large
clusters at the CHMP4 binding site and the Tyr311 (Alix) phos-
phorylation site. On the other hand, other small clusters
throughout all sides of the Bro1 domains make it unreliable to
identify potential NC binding site(s) (Figure S2).
Comparison of Three Bro1 Domain Structures Reveals
a Unique Loop in Alix
Themain structural differences for the three Bro1 domains reside
in the loops connecting the secondary structures. Compared
with the Bro1 domains from HD-PTP and Brox, the Alix Bro1C
(A) as a reference, The modeled HD-PTP:CHMP4 and
ored wheat, cyan and green in (A), (B), and (C), respectively,
he CHMP4B peptide are shown as yellow-colored surface
are shown as dotted lines. See also Figure S2.
d
A B Figure 4. Both Alix and Brox Contain Long a9-a10
Loop on the Same Side of their Bro1 Domains
Phe105 of Alix (ribbons in wheat) is colored red and the a9-
a10 loop of Brox (ribbons in green) is highlighted in
magenta in (A) and (B), Residues from the Brox a9-a10
loop and those in contact with this loop are shown as
sticks. The hydrogen bonds between Lys237 sidechain
andmain chain carbonyls of Gly298 and Pro299 are shown
as dotted lines in (B). See also Figure S3.
Table 2. List of Mutants Generated in the Phe105 Loop
Wild-Type 99F D K G S L F G G S V K L A112
Mutants in
Phe105 loop
104 F D K G S A F G G S V K L A
105 s F D K G S L A G G S V K L A
105 F D K G S L A A A S V K L A
110 F D K G S L F G G S V A L A
104/105 F D K G S A A A A S V K L A
105/110 F D K G S L A A A S V A L A
Phe105 loop extends from Phe99 to Ala112 residue within the Bro1
domain of Alix. Mutated residues are marked in bold face and their
position and name are indicated in the left column.
Structure
A New Functional Determinant in Alix Bro1 Domaindomain has a much longer b1-b2 loop near residue Phe105 that
extends above the main body of the boomerang structure
(Figures 2A and 2D). It is exposed to the solvent in the crystal
lattices (2OEW and 2OEV) with minimal contacts to the rest of
the Bro1 domain or its crystallographic symmetry mates. The
average temperature factor for the Phe105 loop (residues 101-
KGSLFGGS-108), an indicator of structural mobility, is 115 A˚2
compared with 61 A˚2 for the Bro1 domain (2OEW). Furthermore,
this loop adopts drastically different conformations in the Bro1
structure (2OEW) compared with the Bro1-V structure (2OEV)
(Fisher et al., 2007), with a 13.7 A˚ shift of the Ca atoms for
Phe105 (Figure S3), suggesting that it is highly flexible and may
be able to accommodate various binding interfaces.
Brox contains several loops that are longer than those from
HD-PTP and Alix Bro1 domains, such as those between a2-a3,
a3-b1, a4-a5, a5-a6, and a9-a10. The a9-a10 loop is the most
prominent structural differences between Brox and the other
two Bro1 domains (Figure 4). It is centered at residue Pro299
and is anchored on one end by interaction between Pro297
and Leu96 from b1-b2 loop and Pro9 from the N-terminal
loop, and the other end by Val301 packing against Tyr291 from
a9, Trp4 from the N-terminal loop, and His306 from a10. The
middle section of the loop near Pro299 is prodded up toward
solvent through two hydrogen bonds between the side chain of
Lys237 and main chain carbonyls from Gly298 and Pro299 (Fig-
ure 4B). This Pro299 loop also has higher temperature factors
(57 A˚2) compared with the Bro1 domain (35 A˚2), indicating its
flexible nature.
In comparing the two distinctive long loops from Alix and Brox,
it is apparent that they both reside at the same convex surface
of their respective Bro1 domains, and they contain multiple
glycines that allow for flexibility. It is therefore plausible that
this similar structural feature of each Bro1 domain may offer
functional specificities that differentiate them from other Bro1
domain homologs, as described below for the Phe105 loop of
Alix.
The Alix Phe105 Loop Plays an Essential Role
in HIV Release
To examine the role of Phe105 loop in Alix function, we intro-
duced alanine mutations of residues located between 99 and
112 within the loop (Table 2) and analyzed the ability of mutant
Bro1 domain or Alix to rescue the release defects of HIV-1
PTAP- and PTAP-/YP- mutants. As this loop extends beyondStructure 19, 1485–1495, October 12,the body of the boomerang structure with little
contacts with other Bro1 domain residues, the
alanine mutations are unlikely to compromise
the native fold of the domain. Mutation of105-Phe-Gly-Gly-107 residues localized at the tip of the loop
(Bro1-105 mutant) resulted in a complete loss of Bro1 activity
in the virus rescue assay (Figure 5A, lane 5). Identical results
were obtained when leucine or lysine residue at positions
104 and 110 (Bro1-104 and Bro1-110 mutants) were mutated
individually or in combination with changes in neighboring resi-
dues (Figure 5A, lanes 4, 5, 7, and 8). Interestingly, the loss
of Bro1 activity for the Phe105 loop mutants is as severe as
that seen following the mutation of the CHMP4 binding
site (Bro1-I212D mutant) (Figure 5A, lane 3), demonstrating
that the Phe105 loop plays a critical role in the Bro1 domain
function.
To test the role of the Phe105 loop in the context of full-length
Alix, the abovementioned mutations were introduced in Alix, and
their effect on its ability to rescue virus release was assessed.
The WT protein Alix rescued the release of the HIV-1 PTAP-
mutant efficiently, in contrast to both Alix-I212D and Alix-
F676D mutants that failed to function in this assay, because
they lost the essential bindings to CHMP4 and the p6 domain
of Gag, respectively (Fisher et al., 2007; Usami et al., 2007) (Fig-
ure 5B, lanes 2–4). Similarly, substitution of 105-Phe-Gly-Gly-
107 residues to alanines in Alix (Alix-105 mutant) led to about
an 8- to 9-fold reduction in its ability to promote HIV-1 release
(Figures 5B, lane 7, and 5C). A comparable outcome was
observed when individual (Alix-105 s mutant, Figure 5B, lane 6)
or multiple residues (Alix-104/105 and 105/110 mutant, Fig-
ure 5B, lanes 9 and 10) were mutated in the Bro1 Phe105 loop.
Together these results demonstrate that Phe105 loop in the
Bro1 domain is required for efficient Alix-mediated HIV-1 release
and reveal a new key functional determinant in Alix.2011 ª2011 Elsevier Ltd All rights reserved 1489
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Figure 5. Phe105 Loop in Bro1 Domain Is Critical
for Alix-Mediated HIV-1 Release
(A and B) Mutation of residues located at the tip of Phe105
loop in the Bro1 domain (A) or Alix (B) interfere with their
ability to rescue the release of pNL4-3 PTAP-/YP- and
pNL4-3 PTAP- mutant viruses, respectively. 293T cells
were transfected with pNL4-3 PTAP-/YP- (panel A) or
pNL4-3 PTAP- (B) proviral DNA alone (lane 1), with
HA-Bro1 domain or HA-Alix (lane 2), with the indicated
HA-Bro1 domain (panel A, lanes 3–8) or Alix (B, lanes 3–10)
Phe105 loop mutants. Cells and viruses were collected
24h post-transfection and their protein content was
analyzed by SDS-PAGE and western blot using an anti-
capsid antibody. Expression of Bro1 or Alix and their
mutants was detected using an anti-HA antibody. HIV-1
release ratio (values in percentage) was calculated using
the following: release ratio = virus-associated Gag/ cell-
associated Gag, and is shown under panels.
(C) Relative virus release efficiencies of Alix Phe105 loop
mutants was evaluated in three independent experiments
and expressed relative to theWT Alix. Error bars represent
standard deviations.
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A New Functional Determinant in Alix Bro1 DomainMutations in Phe105 Loop Do Not Compromise
Interaction with Gag
The Bro1 domain of Alix interacts with the NC domain of Gag
(Dussupt et al., 2009; Popov et al., 2008). This interaction is
required for Alix mediated release of HIV-1 since mutations of
residues located in the first half of the Bro1 domain caused
a near obliteration of Alix ability to trigger virus release rescue
of HIV-1 PTAP- (Dussupt and Bouamr, unpublished data). Simi-
larly mutations of residues in the Phe105 loop also caused
a significant decrease in Bro1 and Alix mediated HIV-1 release
as demonstrated above. It is unclear whether the disruption of
the Phe105 loop of Bro1 interfered with its ability to interact
with Gag. To address this question, we tested the ability of
HA-tagged Phe105 loop mutants to bind a GST-NC-p6 fusion
protein using pull-down assays. Our results showed that these
mutants retained the ability to engage in interactions with HIV-
1 Gag (Figure 6A, lanes 3-14). Phe105 loop mutants’ interactions
with NC are specific since they were lost when NC basic resi-
dues, the sites previously identified to be involved in binding
the Bro1 domain (Dussupt et al., 2009), were disrupted (mutant1490 Structure 19, 1485–1495, October 12, 2011 ª2011 Elsevier Ltd All rights reserveNC-p6RKI) (Figure 6B). Together these data
indicated that the failure of the Phe105 loop
mutants to efficiently promote HIV-1 release re-
sulted from a defect other than the absence of
interaction(s) with HIV-1 Gag.
Phe105 loop Alix mutants retain
interactions with CHMP4
The ability of Bro1 domain to recruit CHMP4
isoforms (Fisher et al., 2007; Katoh et al., 2003,
2004; Usami et al., 2007) is a key functional
determinant of Alix, as this is required for
HIV-1 budding (Fisher et al., 2007; Usami
et al., 2007) and separation of two daughter cells
at the completion of cytokinesis (Carlton and
Martin-Serrano, 2007; Morita et al., 2007). As
mutation of the Phe105 loop compromised theability of Bro1 and Alix to rescue the release of defective HIV-1
viruses that lack access to the Tsg101/PTAP pathway, we exam-
ined whether such mutations interfered with Bro1-CHMP4
binding. HA-tagged Phe105 loop Bro1 mutants were assessed
for their ability to capture Flag-tagged CHMP4B proteins. The
latter were found in complex with single and multiple Phe105
loop mutants (Figure 7A, lanes 4-8), unlike the Bro1-I212D
variant that lacks the CHMP4 binding site (lane 3). Identical
results were obtained when the Phe105 loop mutations were
examined in the context of full length Alix (Figure 7B), indicating
that the disruption of residues in the Phe105 loop had no effect
on CHMP4-Alix binding and is not the cause for their inability
to mediate virus release.
DISCUSSION
HIV-1 Gag recruits Alix as a bridge protein to access members
of the host ESCRT pathway in order to promote membrane
fission and virus release. Gag recruits Alix via two domains: the
N-terminal Bro1 and the central V domains that engage the NCd
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Figure 6. Phe105 Loop Bro1 Mutants Bind HIV-1 NCp6 Domain
GST, GST-NCp6 (A) or GST NC-p6 RKI mutant (B) fusion proteins were ex-
pressed in E. coli, captured on Glutathione conjugated beads and then
subsequently incubated with lysates from 293T cells expressing WT HA-Bro1
domain or the indicated Phe105 loop Bro1mutants. Captured proteins and cell
lysates were analyzed by SDS-PAGE andwestern blot using anti-HA antibody.
GST fusion proteins were visualized by Coomassie blue staining.
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Figure 7. The Phe105 Loop Mutants Retain Binding to CHMP4B
The Phe105 loopmutant versions of Bro1 domain (A) or full-length Alix (B) were
tested for their ability to bind CHMP4B in immunoprecipitation assays. 293T
cells were co-transfected with Flag-tagged CHMP4B alone (lane 1), or in
combination with WT HA-Bro1, HA-Alix (lane 2), or the HA tagged indicated
mutant (lanes 3–8). Cells were lysed in RIPA buffer and clear lysates were
incubated with anti-HA antibody-conjugated beads. Both input and immu-
noprecipitated complexes were analyzed by SDS-PAGE and western blot
using the indicated antibodies.
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A New Functional Determinant in Alix Bro1 Domainand p6 domains in Gag, respectively. We and others recently
showed that Bro1 interaction with NC is essential for Alix-medi-
ated HIV-1 release (Dussupt et al., 2009; Popov et al., 2008). This
is not surprising since Bro1 connects HIV-1 Gag to the host
fission machinery by directly binding ESCRT-III member
CHMP4 isoforms (Fisher et al., 2007; Katoh et al., 2003, 2004;
Usami et al., 2007). Comparative structure-function studies of
the Bro1 domains of Alix, HD-PTP and Brox revealed a long
loop that is a unique feature of Alix Bro1 domain centered at
residue Phe105. The latter is required for Alix-mediated HIV-1
release even though its disruption had no effect on Bro1 ability
to recruit CHMP4B or interact with Gag. Bro1 Phe105 loop struc-
tural and functional properties indicate it is essential for Alix
function in HIV-1 release.
It is therefore clear that the Bro1 domains of Alix, HD-PTP and
Brox have common and differential properties. They all contain
a conserved CHMP4 binding site located at the concave surface
of their boomerang structure, and they are capable of bindingNC
through an interface that appears distinct from the extruding
loops at the top of the convex surface. The Phe105 loop of AlixStructure 19, 1485–1offers a distinct function: the rescue of HIV-1 PTAP- and
PTAP-/YP mutant viruses, and is independent of its ability to
bind either NC or CHMP4. This new functional determinant
suggests potential new exclusive binding partners through this
unique loop. The structural characteristics of this loop suggest
high flexibility with a dominant presence of glycine residues,
making it amenable to conformational changes and interaction
with multiple partner proteins. It is also interesting to note that
the hydrophobic LF or IF motif flanked by flexible residues of
the Phe105 loop is highly conserved among Alix proteins from
most known metazoan species including C. elegans (McCul-
lough et al., 2008), suggesting its potential role as a conserved
protein-protein binding surface.
Alix functions as a scaffold protein in multiple cellular pro-
cesses (Carlton and Martin-Serrano, 2007; Ichioka et al., 2005;
Katoh et al., 2003; Mahul-Mellier et al., 2008; Martin-Serrano495, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1491
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A New Functional Determinant in Alix Bro1 Domainet al., 2003a; Matsuo et al., 2004; Missotten et al., 1999; Morita
et al., 2007; Odorizzi, 2006; Odorizzi et al., 2003; Pan et al.,
2006, 2008; Sadoul, 2006; Sette et al., 2010; Vito et al., 1999;
Zhou et al., 2010) and appears to fulfill a similar function in
HIV-1 release. It binds Gag during virus assembly (Jouvenet
et al., 2011) and is believed to play a key role in the recruitment
of activated CHMP4 isoforms at the budding neck (Fisher et al.,
2007; Pires et al., 2009; Strack et al., 2003; Usami et al., 2007).
How Alix participates in such function is not yet understood.
However, the role of the Bro1 domain interactions with cellular
CHMP4 factors is clearly essential for these functions (Fisher
et al., 2007; McCullough et al., 2008; Usami et al., 2007), under-
scoring the role of Alix Bro1 domain as a scaffold protein during
HIV-1 assembly and release. In compliance with such a role,
comparison of the crystal structures of the Bro1 domain of Alix,
HD-PTP and Brox (Figure 2) identified an additional docking
region in the Bro1 domain of Alix at the tip of the Phe105 loop.
The N-terminal 423 residues of Alix, but not those from HD-PTP
or Brox, have been shown to bind the C-terminal fragment of
RabGAPLP or RabGAP-5 containing SH3 and RUN domains
(Haas et al., 2005; Ichioka et al., 2005). RUN domains are
commonly involved in regulation of small GTPase functions (Call-
ebaut et al., 2001; Haas et al., 2005; Ichioka et al., 2005). A recent
crystal structure of Rab6 in complex with the RUN domain of
Rab6IP1 showed a conserved hydrophobic interface between
the switch I and II regions of Rab6 and the a1 and a8 helices of
Rab6IP1 RUN domain (Recacha et al., 2009). Since the Phe105
loop of Alix is reminiscent of the highly conserved Phe residues
from the switch I and II regions of Rab6, we considered that
Phe105 loop might be able to dock onto the conserved hydro-
phobic patches at the RUN domain of RabGAPLP. However,
Bro1-105 loop mutants retained binding to RabGAPLP in immu-
noprecipitation assays (data not shown) excluding its involve-
ment in interactions with Phe105 loop. We also ruled out
Nedd4-1 (Sette et al., 2010) as the Phe105 loop binding partner,
since both Bro1 and Alix Phe105 mutants retained interactions
with endogenous and exogenously expressed Nedd4-1 proteins
(data not shown).
Surprisingly, Brox appears to contain a unique a9-a10 loop
located on the same surface of boomerang structure that is
also highly conserved among metazoans (Ichioka et al., 2008)
(Figures 2 and 4). Whether this loop confers distinctive function
for Brox or allows it to bind exclusive partners remains to be
determined. Both Alix and Brox deploy loops on the same side
of their Bro1 domains suggesting the conservation of structural
features of high functional significance. It is thus possible that
the Brox—and possibly HD-PTP, which also bind the NC domain
of HIV-1 Gag (Dussupt et al., 2009)—might utilize loops to
bind cellular factors important for facilitating HIV-1 release in
an ESCRT-dependent (through the PTAP L domain) or ESCRT-
independent manner, (i:e inducing membrane curvature) (Popov
et al., 2009).
Several lines of evidence support a role for loops such as
Phe105 in the recruitment of cellular factor(s) critical for Alix-
mediated membrane fission: i) Alix carrying a mutated Phe105
loop failed to rescue HIV-1 PTAP-, a mutant known to be
impaired in late steps of virus abscission from the cell
membrane. ii) Alix carrying mutations in residues at the tip of
Phe105 loop cease to function in virus release, suggesting the1492 Structure 19, 1485–1495, October 12, 2011 ª2011 Elsevier Ltdloop is designed for capture. iii) The Phe105 loop is a flexible
structure as emphasized by the large conformational differences
it adopts in Bro1 versus Bro1-V (Figure S3), underscoring its
amenability for recruitment (Fisher et al., 2007).
Alix appears to be recruited during assembly (Jouvenet et al.,
2011) and becomes subsequently active at the budding neck
where it interacts with CHMP4 filaments/rings (Pires et al.,
2009) as well as downstream cellular factors to promote mem-
brane fission. Owing to this role as a scaffold protein, it is thus
not surprising that Alix (and Brox) deploys loop(s) to interact
with additional cellular factors necessary for membrane fission,
a complex process comprised of an orchestrated set of events
involving interactions with host proteins, membrane lipids and
cytoskeleton (Pan et al., 2008). It is important to note that Alix
Phe105 loop mutant cease to function even though they retain
binding to a key member of the host fission machinery
CHMP4, suggesting that Phe105 loop is the acceptor site of
a cellular factor that is an essential part of the host membrane
fission pathway. Efforts toward the identification of the Phe105
loop’s binding factor are underway and should further our under-
standing of Alix function inmembrane fission during virus release
as well as other cellular processes.
EXPERIMENTAL PROCEDURES
Proviral Constructs and Expression Vectors
The wild-type (WT) full-length HIV-1 molecular clone pNL4-3 (Adachi et al.,
1986) and its derivatives p6 mutants were previously described (Dussupt
et al., 2009). The L-domain mutants PTAP- and PTAP-/YP- contain the
PTAP to LIRL mutation (Huang et al., 1995) alone or in combination with the
YP to LV mutation in p6 (Dussupt et al., 2009), respectively. Mammalian
expression vectors for N-terminal HA-tagged Alix/AIP-1, HD-PTP, Brox, Alix
Bro1 domain and HD-PTP Bro1 domain were previously described (Dussupt
et al., 2009). Point mutations were introduced in Alix Bro1 using the Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla, CA). The CHMP4B
expression vector was generated by PCR amplification from CHMP4B cDNA
(GeneCopoeia, Germantown,) and subcloning into p3XFLAG-myc-CMV-26
vector (Sigma, St. Louis, MO) between NotI/EcoRI sites respectively for
N-terminally 3XFLAG tagged CHMP4B. For GST pull-down, the HIV-1 NC
and NC-p1-p6 coding region were amplified from WT pNL4-3 and subcloned
in pGEX-5X-2 (GE Healthcare Biosciences, Piscataway, NJ) between BamHI/
EcoRI sites.
Virus Release Analysis
293T cells were maintained in DMEM supplemented with 10% fetal bovine
serum and seeded (2.5 millions) in T25 flasks and transfected the following
day using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to manu-
facturer instructions. 24 hours after transfection, cell culture media was filtered
through 0.45 mmfilter and pelleted at 150,000 g for 1 hr on a 20% (w/v) sucrose
cushion. After centrifugation virus pellets were resuspended in Laemmli buffer
containing 5% (v/v) bmercaptoethanol. Cells were washed in cold PBS, pel-
leted at 1,0003 g and lysed in 200 ml of Igepal lysis buffer (1% [vol/vol] Igepal,
50 mM Tris-HCl, pH 8.0, 150 mMNaCl) and protease inhibitor cocktail (Roche,
Indianapolis, IN) for 20 min on ice. Cell lysates were cleared by centrifugation,
and supernatants were collected and boiled in 2x Laemmli sample buffer.
Virion pellets and cell extracts were analyzed by SDS-PAGE and western
blot using an anti-HIV-1 p24 monoclonal antibody (clone 183-H12-5C) or
NEA-9306. Expression of Alix WT and mutants was detected using a mono-
clonal antibody anti-HA (Sigma, St Louis, MO).
Immunoprecipitation Assays
293T cells (2 millions) were seeded into T25 flasks and transfected the
following day using Lipofectamine 2000. Forty-eight hours post-transfection,
the cells were harvested, washed twice in cold PBS and lysed in RIPA bufferAll rights reserved
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A New Functional Determinant in Alix Bro1 Domain(0.5% [v/v] Igepal, 50 mM HEPES, pH 7.3, 150 mM NaCl, 2 mM EDTA, 20 mM
b-glycerophosphate, 0.1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, 0.5 mM DTT
and Complete protease inhibitor cocktail [Roche, Indianapolis, IN]) for
20 min on ice. Cell lysates were centrifuged at 16,000 3 g, 4C, for 15 min
and supernatants were incubated at 4Cwith either anti-HAmouse conjugated
to EZview agarose beads (Sigma, St. Louis, MO). The beads were then
extensively washed in RIPA buffer prior to two successive elutions with the
appropriate peptide (100 mg/ml). Immunoprecipitation eluates and cell lysates
(input fractions) were analyzed by SDS-PAGE and western blot with anti-HA
or anti-Flag M2 antibodies (Sigma, St. Louis, MO).
GST Pull-Down Assays
The pGEX-NCp6 or NC and empty vector were transformed into BL21 (DE3)
pLysS E. coli (Stratagene). Cultures in exponential phase were induced with
1 mM isopropyl b-d-thiogalactopyranoside for 4 hr at 37C. Bacteria pellets
were resuspended in Bacteria Lysis Buffer (BLB [50 mM Tris-HCl pH8.0,
1% (w/v) sucrose, 100 mM ZnCl2, 10% Glycerol, 0.1 mM PMSF, 0.1 mM
DTT and protease inhibitor cocktail]). Lysozyme was added at a final concen-
tration of 500 mg/ml and the samples were incubated on ice for 2h and
sonicated. Lysates were cleared by centrifugation at 16,000 3 g, 4C, for
15 min. Supernatants containing GST proteins were incubated with gluta-
thione-Sepharose 4B beads (GE Healthcare Biosciences, Piscataway, NJ)
for 2 hr at 4C. The beads were then washed three times in BLB and blocked
overnight in 5%BSA in BLB. The day after, the beadswere washed extensively
in BLB andMammalian Lysis buffer (MLB, [0.5% Igepal, 50mMHEPES pH 7.3,
100 mM NaCl, 100 mM ZnCl22, 10% Glycerol, 20 mM b-glycerophosphate,
0.1mMNa3VO4, 1mMNaF, 1mMPMSF, 0.5 mMDTT andComplete protease
inhibitor cocktail [Roche, Indianapolis, IN]) and then incubated with 293T cell
lysates containing the proteins of interest for 3h at 4C. The complexes were
washed four times in MLB and eluted with 10 mM reduced-glutathione in
50mM Tris-HCl pH 8.0. Eluates and cell lysates (input fractions) were analyzed
by SDS-PAGE and western blot with the appropriate antibodies.
Protein Expression and Purification
Brox-Bro1 domain (residues 2 to 374) and human HD-PTP Bro1 domain (resi-
dues 2 to 361) were cloned in a modified pET30a(+) vector (EMD Biosciences,
San Diego, CA) between the NdeI and NotI sites. Forward primers were de-
signed so that the expressed proteins carried a N-terminal 6 3 Histidines
tag followed by a cleavage site for the tobacco etch virus (TEV) protease.
The expression vectors were transformed into E. coli BL21 (DE3) cells and
protein expression was induced with 0.5 mM isopropyl-b-d-thiogalactoside
(IPTG) at OD600 = 0.6–0.8 and grew overnight at 15
C. Cells were lysed in
a buffer containing 25 mM Tris-HCl, pH 8.0, 125 mM NaCl and 10 mM imid-
azole and lysed by sonication. Cleared cell lysates were purified by nickel
affinity chromatography on a HisPrep FF 16/10 affinity column (GE Healthcare
Biosciences, Piscataway, NJ) followed by TEV digestion at 4C for 12 hr. The
proteins were further purified by size-exclusion chromatography with a
Superdex200 (26/60) column (GE Healthcare Biosciences, Piscataway, NJ)
in a buffer containing 25 mM Tris-HCl pH 8.0 and 125 mM NaCl. A second
nickel affinity chromatography was used to remove the His6-tagged TEV
and digested expression tags. The final protein buffer contained 25 mM Tris-
HCL pH 8.0 and 125 mM NaCl.
Crystallization and Structure Determination
Brox-Bro1 domain (residues 2 to 374) was concentrated to 0.8 mg/ml and
crystallized in 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) buffer at
pH 6.5 and 1 M sodium formate at 18C. HD-PTP-Bro1 domain (residues 2
to 356) was concentrated to 28 mg/ml and crystallized in 0.1 M MES buffer
at pH 5.5 containing 16% PEG 3350 and 0.3 M magnesium acetate at 18C.
Large single crystals grew in about one week. The crystals were transferred
into a solution containing 30% ethylene glycol (for Brox) or 15% glycerol (for
HD-PTP) and were flash frozen in liquid nitrogen. Diffraction data were
collected at beamline 23-ID-D of the Argonne National Laboratory (Argonne,
IL) or the beamline X29 of the Brookhaven National Laboratory (Upton, NY).
The diffraction data were processed with the HKL2000 package (Zbyszek
Otwinowski, 1997). The Bro1 domain of Brox crystallizes in space group P63
with one molecule in the crystallographic asymmetric unit (ASU) and that of
HD-PTP crystallizes in space group P1 with two molecules in the ASU. Struc-Structure 19, 1485–1tures of both were determined bymolecular replacement with program Phaser
(McCoy et al., 2007) from the CCP4 program suite (Potterton et al., 2003), using
the crystal structure of Alix Bro1 domain as a searchmodel (Fisher et al., 2007).
The structural models were built and refined using programs COOT (Emsley
and Cowtan, 2004) and PHENIX (Adams et al., 2010), respectively. Electro-
statics surfaces were calculated by program Delphi (Honig and Nicholls,
1995). All structure figures were prepared with program Pymol (Schro¨dinger,
LLC.).
Modeling of the CHMP4B Peptide in Complex with HD-PTP and Brox
The Bro1 domains of HD-PTP and Brox were superimposed onto the Alix
Bro1:CHMP4B complex structure (3C3Q) (McCullough et al., 2008). The re-
sulting HD-PTP:CHMP4B and Brox:CHMP4B complex were manually
adjusted to remove clashes using program COOT (Emsley and Cowtan,
2004) and subjected to energy minimization using the relax mode of the
Rosetta program (v3.2) (Bradley, et al., 2003).
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Coordinates and structure factor files have been deposited in the RCSB
Protein Data Bank with accession code 3R9M and 3RAU.
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